APGE vs. ELAN, VRNA, LEGN, TGTX, GRFS, LNTH, TLX, NUVL, AXSM, and ADMA
Should you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Elanco Animal Health (ELAN), Verona Pharma (VRNA), Legend Biotech (LEGN), TG Therapeutics (TGTX), Grifols (GRFS), Lantheus (LNTH), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Nuvalent (NUVL), Axsome Therapeutics (AXSM), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.
Apogee Therapeutics vs. Its Competitors
Apogee Therapeutics (NASDAQ:APGE) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.
Elanco Animal Health has a net margin of 4.60% compared to Apogee Therapeutics' net margin of 0.00%. Elanco Animal Health's return on equity of 6.78% beat Apogee Therapeutics' return on equity.
Apogee Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500.
Apogee Therapeutics currently has a consensus target price of $94.60, indicating a potential upside of 124.01%. Elanco Animal Health has a consensus target price of $15.17, indicating a potential upside of 6.66%. Given Apogee Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Apogee Therapeutics is more favorable than Elanco Animal Health.
Elanco Animal Health received 116 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 96.55% of users gave Apogee Therapeutics an outperform vote while only 54.96% of users gave Elanco Animal Health an outperform vote.
79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 42.8% of Apogee Therapeutics shares are held by insiders. Comparatively, 0.9% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Apogee Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
In the previous week, Apogee Therapeutics had 1 more articles in the media than Elanco Animal Health. MarketBeat recorded 4 mentions for Apogee Therapeutics and 3 mentions for Elanco Animal Health. Apogee Therapeutics' average media sentiment score of 0.55 beat Elanco Animal Health's score of 0.40 indicating that Apogee Therapeutics is being referred to more favorably in the media.
Summary
Elanco Animal Health beats Apogee Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Apogee Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apogee Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:APGE) was last updated on 6/12/2025 by MarketBeat.com Staff
